The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: The current evidence

  title={The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: The current evidence},
  author={Lawrence Leeman and Umesh Acharya},
  journal={Journal of Obstetrics and Gynaecology},
  pages={467 - 472}
  • L. LeemanU. Acharya
  • Published 1 January 2009
  • Medicine, Biology
  • Journal of Obstetrics and Gynaecology
Summary Women suffering from anovulatory infertility are frequently diagnosed with polycystic ovary syndrome (PCOS), which is a varied condition of ovarian dysfunction characterised by hyperandrogenaemia and abnormal ovarian morphology. PCOS has been associated with insulin resistance, leading to the insulin-sensitising agent, metformin, being investigated as a useful therapy for the reinstatement of normal ovarian function and regular ovulation. While some trials and meta-analyses have… 

The conservative treatment in adolescents with the Polycystic ovary syndrome

Teen treatment should be individualized depending on a number of peculiarities that have to be taken into account: menstruation disorders, mastopathies and ovarian dystrophies, hyperandrogenism syndrome, sexually transmitted diseases and other associated disorders.

d-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review

  • N. GalazisM. GalaziW. Atiomo
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2011
Heterogeneity observed in the methodologies of each study, the scarcity of relevant studies and the small sample sizes used prohibit reliable conclusions to be drawn, therefore, more studies must be conducted in the future to evaluate accurately the effects of DCI in PCOS.

Finasteride ( plus Oral Contraceptive pill ) vs Metformin in Treatment of Polycystic Ovary Syndrome-Related Infertility : a Prospective Randomized Trial

Finasteride has a good promising effect in the treatment of infertility due to PCOS, as more patients responded to an oral finasteride-OCP combination in comparison to those responded toan oral metformin monotherapy and the difference in the pregnancy rate of the two groups was not significant.

Polycystic Ovarian Syndrome: Insights into Pathogenesis, Diagnosis, Prognosis, Pharmacological and Non-Pharmacological Treatment

Patients with PCOS are at increased risk for developing reproductive, metabolic and cardiovascular disorders, including infertility, insulin resistance, diabetes mellitus type 2, hypertension and atherosclerosis.

Increasing of PCOs among Young Females

Appropriate diagnosis and administration of PCOS is crucial to address patient concerns yet additionally to anticipate future metabolic, endocrine, psychiatric, and cardiovascular complications.

Metformin and N-acetyl Cysteine in Polycystic Ovarian Syndrome–-A Comparative Study:

N-acetyl Cysteine had better improvement in clinical, biochemical and hormonal profile than Metformin in PCOS patients, considering its limited adverse effects and can be used as a substitute for insulin reducing medications in treatment ofPCOS patients.

A prospective, comparative study of N-acetyl cysteine with metformin on clinical profile in an ovulatory infertile woman with PCOS

NAC can be used as a substitute for insulin-sensitizing agent in treatment of PCOS because of its less side effect comparing to metformin, and better improvement of metabolic and hormonal profile was observed in N acetyl cysteine group.

Effect of auriculotherapy on menstrual irregularities in single girls with polycystic ovarian syndrome and aged 18-35 years in Isfahan in 2012

Medicational treatment and auriculotherapy are both effective on menstruation disorders, but auricULotherapy is more effective on reduction of menstrual disorders, compared to medicational therapy.

Effects of N-acetylcysteine and metformin treatment on the stereopathological characteristics of uterus and ovary

NAC can control and treat pathological parameters and help as a harmless drug in the treatment of women with PCOS and restore the condition to normal.

Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.

The SIRT1 expression in the ovary tissue decreases in PCOS rats but can be up-regulated after Ex or MF treatment, which suggests exenatide may be therapeutic for PCOS by up-regulating the SITR1 expression.



Insulin-lowering agents in the management of polycystic ovary syndrome.

In a high percentage of patients, treatment with metformin is followed by regularization of menstrual cycle, reduction in hyperandrogenism and in cardiovascular risk factors, and improvement in response to therapies for induction of ovulation.

Drugs for anovulatory infertility in polycystic ovary syndrome

Options for drug treatment may seem more straightforward, but a multicentre placebo controlled trial of metformin reported in this week's BMJ by Moll and colleagues challenges that view.

Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology

This article focuses on the recent change in attitudes to polycystic ovarian syndrome arising from the link with insulin resistance—a concept that not only has major implications for the health of affected women but also offers a potential for new treatments.

Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance

  • Jolanta NawrockaA. Starczewski
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2007
Assessment of the effects of metformin treatment in PCOS patients both with and without insulin resistance found significant decreases in luteinizing hormone and fasting insulin concentrations and the free androgen index (FAI), and significant increases in follicle-stimulating hormone (FSH)/LH ratio and SHBG concentration.

Current perspectives in polycystic ovary syndrome.

The purpose of this review is to examine the clinical course of this syndrome, which spans adolescence through menopause, and suggest a simple and cost-effective diagnostic evaluation to screen the large numbers of women who may be affected.

Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.

Clomiphene is superior to metformin in achieving live birth in infertile women with the polycystic ovary syndrome, although multiple birth is a complication.

Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome.

Metformin plus CC appears to be very effective for achievement of pregnancy compared to CC alone and no RCTs directly compare metformin to CC but the need for such a trial exists.

Insulin-sensitizing agents in polycystic ovary syndrome.

Since almost all obese PCOS women and more than half of those of normal weight are insulin resistant, and therefore present some degree of hyperinsulinemia, the use of insulin sensitizers should be suggested in most patients with PCOS.